Prof. Dr. Frank Lampe: Alternative cancer therapy for Non-Hodgkin lymphoma
Non-Hodgkin lymphomas are a heterogeneous group of cancers that originate in the lymphocytes.
A distinction is made between the various lymphomas with regard to their prognosis and therapy according to the cell types and the clinical and molecular properties. Worldwide, around 144,800 people developed non-Hodgkin's lymphoma in 2019. It is primarily a disease of an older age. At the time of diagnosis, the women were on average 69 years old and the men 67.
The increased age-standardized incidence rates have to be seen due to changed diagnostic criteria, because the chronic lymphatic leukemia today is often apportioned to the low-grade non-Hodgkin lymphomas.
With a survival rate of 69 percent for women and 67 percent for men, the relative five-year survival rate is relatively good. But the probability of death remains higher as the disease progresses
With the help of our Non-Hodgkin lymphoma enzyme, the spread and growth of malignant tumors can be slowed down in a targeted manner.
We recommend taking one capsule two or three times.